MA49751B1 - Agents antifongiques à activité améliorée en ph acide - Google Patents

Agents antifongiques à activité améliorée en ph acide

Info

Publication number
MA49751B1
MA49751B1 MA49751A MA49751A MA49751B1 MA 49751 B1 MA49751 B1 MA 49751B1 MA 49751 A MA49751 A MA 49751A MA 49751 A MA49751 A MA 49751A MA 49751 B1 MA49751 B1 MA 49751B1
Authority
MA
Morocco
Prior art keywords
infections
enfumafungin
useful
acidic
under acidic
Prior art date
Application number
MA49751A
Other languages
English (en)
Other versions
MA49751A (fr
Inventor
Gonzalez David A Angulo
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49751(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MA49751A publication Critical patent/MA49751A/fr
Publication of MA49751B1 publication Critical patent/MA49751B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

Les composés antifongiques triterpénoïdes dérivés de l'enfumafungine sont utilisés pour traiter ou prévenir les infections fongiques se produisant en ou sous conditions acides, où le ph est inférieur à environ 7, du fait que leur efficacité est, de façon inattendue, améliorée sous de telles conditions. Les triterpénoïdes dérivés de l'enfumafungine (ou des sels ou hydrates de qualité pharmaceutique de ces derniers) sont des inhibiteurs de la synthèse des (1,3)-ß-d-glucanes et sont utilisables dans le traitement ou la prévention d'infections à levures ou à champignons filamenteux qui se développent dans les zones anatomiques à ph bas, telles que la cavité vaginale, ou sous des conditions d'environnement local acides telles que celles observées dans des abcès fongiques, dans l'empyème, ou dans les infections du tractus gastro-intestinal supérieur.
MA49751A 2017-08-04 2018-07-31 Agents antifongiques à activité améliorée en ph acide MA49751B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
PCT/US2018/044619 WO2019028034A1 (fr) 2017-08-04 2018-07-31 Agents antifongiques à activité améliorée en ph acide

Publications (2)

Publication Number Publication Date
MA49751A MA49751A (fr) 2020-06-10
MA49751B1 true MA49751B1 (fr) 2022-12-30

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49751A MA49751B1 (fr) 2017-08-04 2018-07-31 Agents antifongiques à activité améliorée en ph acide

Country Status (24)

Country Link
US (2) US11534433B2 (fr)
EP (2) EP4169514A1 (fr)
JP (1) JP7214714B2 (fr)
KR (1) KR20200044823A (fr)
CN (1) CN111093655A (fr)
AU (1) AU2018309718A1 (fr)
BR (1) BR112020002290A2 (fr)
CA (1) CA3071940A1 (fr)
DK (1) DK3661503T3 (fr)
EA (1) EA202090445A1 (fr)
ES (1) ES2932658T3 (fr)
FI (1) FI3661503T3 (fr)
HR (1) HRP20221414T1 (fr)
HU (1) HUE060508T2 (fr)
LT (1) LT3661503T (fr)
MA (1) MA49751B1 (fr)
MD (1) MD3661503T2 (fr)
MX (1) MX2020001399A (fr)
PL (1) PL3661503T3 (fr)
PT (1) PT3661503T (fr)
RS (1) RS63746B1 (fr)
SI (1) SI3661503T1 (fr)
TW (1) TWI805600B (fr)
WO (1) WO2019028034A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228036A1 (en) * 2019-02-27 2021-09-23 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
KR20220009416A (ko) * 2019-05-16 2022-01-24 싸이넥시스, 인크. 칸디다 아우리스 탈집락화를 위한 항진균제
WO2022140646A1 (fr) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Schéma posologique de l'otéséconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
WO2007127012A1 (fr) 2006-04-03 2007-11-08 Merck & Co., Inc. Agents antifongiques
UA105639C2 (uk) * 2008-08-12 2014-06-10 Сінексіс, Інк. Протигрибковий засіб
CN104877001B (zh) 2008-08-12 2020-07-03 西尼克斯公司 抗真菌制剂
US10174074B2 (en) 2015-01-19 2019-01-08 Scynexis, Inc. Salts and polymorphs of SCY-078
EA201992413A1 (ru) * 2017-04-10 2020-03-16 Сайнексис, Инк. Противогрибковые средства, используемые в комбинации

Also Published As

Publication number Publication date
AU2018309718A1 (en) 2020-02-27
MA49751A (fr) 2020-06-10
US20230364067A1 (en) 2023-11-16
DK3661503T3 (da) 2022-12-12
PL3661503T3 (pl) 2023-01-09
FI3661503T3 (fi) 2022-12-15
CN111093655A (zh) 2020-05-01
MX2020001399A (es) 2020-08-06
LT3661503T (lt) 2022-12-12
JP2020529999A (ja) 2020-10-15
HUE060508T2 (hu) 2023-03-28
ES2932658T3 (es) 2023-01-23
TWI805600B (zh) 2023-06-21
RS63746B1 (sr) 2022-12-30
EA202090445A1 (ru) 2020-06-23
TW201919476A (zh) 2019-06-01
CA3071940A1 (fr) 2019-02-07
WO2019028034A1 (fr) 2019-02-07
KR20200044823A (ko) 2020-04-29
US20200390751A1 (en) 2020-12-17
EP3661503A1 (fr) 2020-06-10
SI3661503T1 (sl) 2023-01-31
US11534433B2 (en) 2022-12-27
JP7214714B2 (ja) 2023-01-30
BR112020002290A2 (pt) 2020-09-08
EP4169514A1 (fr) 2023-04-26
HRP20221414T1 (hr) 2023-01-20
EP3661503B1 (fr) 2022-09-07
MD3661503T2 (ro) 2023-01-31
PT3661503T (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
MA49751B1 (fr) Agents antifongiques à activité améliorée en ph acide
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA42278B1 (fr) Compositions comprenant une souches bactérienne de blautia hydrogenotrophica pour l'utilisation pour le traitement d'infections bactériennes du tractus gastro-intestinal
MA42145B1 (fr) Triazoles agonistes du récepteur apj
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
EP4218754A3 (fr) Méthodes de traitement de la fibrose kystique
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
NZ792518A (en) Formulations for administration of eflornithine
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
WO2018151861A8 (fr) Procédés de traitement de la schizophrénie
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
BR112022017189A2 (pt) Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
DK1166788T3 (da) Lægemidler til ledsygdomme
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
FR3100128B1 (fr) Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA202092190A1 (ru) Композиции и способы для лечения сильного запора
EA202090194A1 (ru) Композиции статинов и способы их применения при лечении синуклеинопатий
MA44513B1 (fr) Formulations injectables de fosnetupitant physiologiquement equilibrees
EA202192257A1 (ru) Комбинация кремния и магния для предупреждения и лечения мышечных судорог
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
EA202090965A1 (ru) Водные композиции биластина